Severity
Low
FDA Drug recall · Reported October 2, 2019
Failed Dissolution Specifications:
Epi Health, LLC recalled minolira (minocycline hydrochloride) extended-release tablets 135 mg* Physician Sample No… - a low-severity action.
minolira (minocycline hydrochloride) extended-release tablets 135 mg* Physician Sample No… was recalled by Epi Health, LLC in October 2, 2019. Reason: Failed Dissolution Specifications:. Check the official notice for the remedy. Verify recall #D-0120-2020 with the FDA Drug before acting.
The recall
Epi Health, LLC issued this low-severity FDA Drug recall-Failed Dissolution Specifications:.
Sourced from official FDA Drug enforcement records. Verify recall #D-0120-2020 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0120-2020) was formally reported on October 2, 2019, with the manufacturer initiating the action on August 26, 2019. It is classified under Low severity (Class III), with a current status of Terminated. Epi Health, LLC is listed as the recalling firm, operating out of Charleston, SC. Federal records list the affected scope as 1,626 5-count bottles.
The documented reason for this recall is: Failed Dissolution Specifications: Distribution data in the federal record shows the product reached: Firm recalling only from EPI Field Representatives.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
1,626 5-count bottles
Related Recalls
6
5 from same agency
minolira (minocycline hydrochloride) extended-release tablets 135 mg* Physician Sample Not for Sale 5 Tablets, Rx Only, Mfg by: Dr. Reddy's Laboratories Limited, FTO-SEZ, Process Unit-01 Devunipalavalasa Village Srikakulam (District) Andhra Pradesh, INDIA. Manufactured for: EPI Health, LLC 134 Columbus St. Charleston, SC 29403 USA. NDC 71403-102-05.
Failed Dissolution Specifications:
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-0120-2020 |
| Date reported | October 2, 2019 |
| Date initiated | August 26, 2019 |
| Recalling firm | Epi Health, LLC |
| Firm location | Charleston, SC |
| Affected scope | 1,626 5-count bottles |
| Distribution | Firm recalling only from EPI Field Representatives. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported October 2, 2019. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.